SuanFarma-Header

SuanFarma-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

OliX Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Post An Enquiry

Korea, Republic Of

German Biotechnology Days 2021

Participation Not Confirmed

Update your events

OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion an...

Lead Product(s): OLX101A

Therapeutic Area: Dermatology Product Name: OLX101A

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $37.2 million Upfront Cash: Undisclosed

Deal Type: Financing December 01, 2020

Details:

Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.